Ubrogepant Beneficial for Treating Migraine During the Prodrome

Follow Drugslib on

Medically reviewed by Drugs.com.

By Elana Gotkine HealthDay Reporter

WEDNESDAY, Nov. 22, 2023 -- Ubrogepant is beneficial for the treatment of migraine when taken during the prodrome, according to a study published online Nov. 15 in The Lancet.

David W. Dodick, M.D., from the Mayo Clinic in Phoenix, and colleagues examined the efficacy, safety, and tolerability of ubrogepant 100 mg versus placebo for acute treatment of migraine when administered during the prodrome in a multicenter, randomized trial. Adults aged 18 to 75 years with at least a one-year history of migraine with or without aura and a history of two to eight migraine attacks per month with moderate-to-severe headache in the three months before screening were included. Participants were randomly assigned to placebo to treat the first qualifying prodrome event and ubrogepant 100 mg to treat the second qualifying prodrome event or vice versa. The safety population included 480 participants and the modified intention-to-treat population included 477 participants.

The researchers found that within 24 hours after a dose, absence of moderate or severe headache occurred after 46 and 29 percent of 418 and 423 qualifying prodrome events that had been treated with ubrogepant and placebo, respectively (odds ratio, 2.09). Adverse events that occurred within 48 hours after study-drug administration were reported after 17 and 12 percent of qualifying prodrome events that had been treated with ubrogepant and placebo, respectively.

"These results emphasize the clinical value of identifying the prodrome in people with migraine and highlight an important opportunity to intervene in the earliest phase of a migraine attack to prevent progression to the headache phase, reduce disability, and improve outcomes," the authors write.

Several authors disclosed ties to biopharmaceutical companies, including AbbVie, which manufactures ubrogepant and funded the study.

Abstract/Full Text (subscription or payment may be required)

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

Source: HealthDay

Posted : 2023-11-23 00:52

Read more

Disclaimer

Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.

Popular Keywords